DE:BIX0 Stock Latest News
Company AnnouncementsBioInvent Issues Supplementary Notice Ahead of Key Extraordinary General Meeting2d ago
Company AnnouncementsBioInvent Launches SEK 430m Rights Issue to Fund Cancer Drug Development4d ago
Company AnnouncementsBioInvent Calls Extraordinary General Meeting to Approve Share Issue and Governance Changes4d ago
Company AnnouncementsBioInvent Wins FDA Fast Track for BI-1808 and Plans SEK 430m Rights Issue Amid Wider Losses4d ago
Company AnnouncementsBioInvent to Present January–September 2026 Interim Report in Webcast5d ago
Company AnnouncementsBioInvent’s BI-1808 Combo Shows Durable Responses in Platinum-Resistant Ovarian Cancer1w ago
Company AnnouncementsBioInvent’s BI-1808 Shows Strong Safety and Early Efficacy in First-in-Human Cancer Trial2w ago
Company AnnouncementsBioInvent Plans CFO Transition as Veteran Finance Chief Retires in 20272w ago
Company AnnouncementsBioInvent Balances Widening Losses With Strong Immuno-Oncology Milestones2M ago- Pre-EarningsBOVNF Upcoming Earnings Report: What to Expect?2M ago
- Company AnnouncementsBioInvent Publishes Key Preclinical Data on TNFR2 Antibodies BI-1808 and BI-19102M ago
Company AnnouncementsBioInvent Wins FDA Fast Track for BI-1808 in High-Need Ovarian Cancer2M agoCompany AnnouncementsBioInvent Data Show FcγR-Targeting Antibodies Boost Checkpoint Therapy and Tackle Resistance3M ago
- Company AnnouncementsBioInvent’s BI‑1808 Shows Strong Responses and Immune Activation in Advanced CTCL4M ago
Company AnnouncementsBioInvent’s BI-1206 Triplet Delivers Strong Efficacy and Safety in Refractory NHL4M ago- Company AnnouncementsBioInvent to Showcase New BI-1206 and BI-1808 Hematology Data at Stockholm KOL Event5M ago
Company AnnouncementsBioInvent’s BI-1808 Plus Keytruda Shows Strong Ovarian Cancer Signal in Phase 2a5M ago
Company AnnouncementsBioInvent Showcases Promising Ovarian Cancer Antibody BI-1808 in Virtual KOL Event5M agoCompany AnnouncementsBioInvent to Showcase Promising BI-1206 Triplet Data in Relapsed NHL at EHA 20265M ago